Concizumab improves clot formation in hemophilia A under flow.

ABSTRACT:

Background

Inhibition of tissue factor pathway inhibitor (TFPI) is an emerging therapeutic strategy for treatment of hemophilia. Concizumab is a monoclonal antibody that binds TFPI and blocks its inhibition of factor (F)Xa thereby extending the initiation of coagulation and compensating for lack of FVIII or FIX.

Objectives

The objective of this in vitro study was to evaluate how concizumab affects clot formation in hemophilia A under flow.

Methods

Blood was collected from normal controls or people with hemophilia A. An anti-FVIII antibody was added to normal controls to simulate hemophilia A with inhibitory antibodies to FVIII. Whole blood and recombinant activated FVII (rFVIIa, 25 nM) or concizumab (200, 1000, and 4000 ng/mL) were perfused at 100 s^-1 over

SUBMITTER: Jewell MP 

PROVIDER: S-EPMC11343664 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature